Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR
SKBBYDrugs in Pipeline
61
Phase 3 Programs
31
Upcoming Catalysts
34
Next Catalyst
This month
Market Overview
Stock performance and key metrics
34 upcoming, 8 past
Vinorelbine Phase 3 Est. Readout
Primary completion for Vinorelbine trial (NCT06382142) in Triple-Negative Breast Cancer
SourcePD-1 monoclonal antibody Phase 2 Est. Readout
Estimated primary completion for PD-1 monoclonal antibody trial (NCT06437522) in Head and Neck Squamous Cell Carcinoma. Topline data typically follows completion by weeks to months.
Source32 more catalysts beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Wujia Yizhi granules
Alzheimer's Dementia
Pemetrexed
Non-small Cell Lung Cancer
SI-B001
Non-small Cell Lung Adenocarcinoma
BL-B01D1
Advanced Biliary Tract Cancer
Capecitabine
Metastatic Breast Cancer
Docetaxel or Paclitaxel
Urothelial Carcinoma
Eribulin
HR+HER2- Breast Cancer
Osimertinib
Non-Small Cell Lung Cancer
T-DM1
HER2-positive Breast Cancer
Docetaxel
Non-small Cell Lung Cancer
Paclitaxel
Head and Neck Squamous Cell Carcinoma
SKB264
Metastatic Breast Cancer
Vinorelbine
Triple-Negative Breast Cancer
BL-M07D1
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
A166
HER2-positive Breast Cancer
Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
Non-small Cell Lung Cancer
KL-A167
Nasopharyngeal Carcinoma
Double blind control period A140
Metastatic Colorectal Cancer
Nab-paclitaxel
Triple Negative Breast Cancer
Topotecan
Small Cell Lung Cancer
HSK3486
Sedation or Anesthesia
Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel
HER2-low Breast Cancer
Propofol
Colonoscopy
Irinotecan
Esophageal Squamous Cell Carcinoma
gemcitabine
Nasopharyngeal Carcinoma
KN035 plus Gemcitabine & oxaliplatin
Biliary Tract Neoplasms
Investigator's choice of chemotherapy
Gastric Adenocarcinoma
Pemetrexed+Cisplatin or Carboplatin
Non-small Cell Lung Cancer
Carboplatin
Non-squamous Non-small Cell Lung Cancer
BL-M05D1
Gastric Cancer
Pertuzumab
HER2-positive Breast Cancer
SKB105 for injection Monotherapy
Advanced Solid Tumors
KN035
Solid Tumor
BL-M02D1
Non-small Cell Lung Cancer
KL590586 Capsule
Advanced Solid Tumor
PD-1 monoclonal antibody
Extensive-stage Small-cell Lung Cancer
Axitinib
Renal Cancer
Sacituzumab Tirumotecan
Non-Small Cell Lung Cancer
PD-1
Urothelial Carcinoma
SI-B003
Esophageal Cancer
PRT-064040 nasal spray
Migraine
SKB571 for injection
Lung Cancer (Non-Small Cell)
Clarithromycin
Ovarian Epithelial Cancer
Test product HY0001a for injection
Solid Tumor
Low Dose PRT042 nasal spray
Major Depressive Disorder (MDD
GNC-035
Non-hodgkin's Lymphoma
Test product: HYP-2090PTSA
Safety
Envafolimab+Lenvatinib
Advanced Endometrial Cancer
AP or TP
Non Small Cell Lung Cancer
HY05350 for injection
Advanced Solid Tumor
SKB103 for injection monotherapy
Advanced Solid Tumors
SKB500 Powder for Injection
Small Cell Lung Cancer
Lenvatinib
Advanced Hepatocellular Carcinoma
Envafolimab
Solid Tumor
GNC-038
Diffuse Large B-cell Lymphoma
BL-B01D1 for Injection
Recurrent Glioblastoma
Lenvatinib + Envafolimab
Solid Tumors
SKB518
Lung Carcinoma
KL-A167 Injection
Nasopharyngeal Carcinoma
SKB518 for injection
Advanced Gynecological Malignancies
Osimertinib Mesylate Tablets
Non-small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Wujia Yizhi granules | Phase 3 | Alzheimer's Dementia | - | - |
Pemetrexed | Phase 3 | Non-small Cell Lung Cancer | - | - |
SI-B001 | Phase 3 | Non-small Cell Lung Adenocarcinoma | - | - |
BL-B01D1 | Phase 3 | Advanced Biliary Tract Cancer | - | - |
Capecitabine | Phase 3 | Metastatic Breast Cancer | - | - |
Docetaxel or Paclitaxel | Phase 3 | Urothelial Carcinoma | - | - |
Eribulin | Phase 3 | HR+HER2- Breast Cancer | - | - |
Osimertinib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
T-DM1 | Phase 3 | HER2-positive Breast Cancer | - | - |
Docetaxel | Phase 3 | Non-small Cell Lung Cancer | - | - |
Paclitaxel | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
SKB264 | Phase 3 | Metastatic Breast Cancer | - | - |
Vinorelbine | Phase 3 | Triple-Negative Breast Cancer | - | - |
BL-M07D1 | Phase 3 | Her2-positive/Low-expression Urinary and Digestive Tract Tumors | - | - |
A166 | Phase 3 | HER2-positive Breast Cancer | - | - |
Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection | Phase 3 | Non-small Cell Lung Cancer | - | - |
KL-A167 | Phase 3 | Nasopharyngeal Carcinoma | - | - |
Double blind control period A140 | Phase 3 | Metastatic Colorectal Cancer | - | - |
Nab-paclitaxel | Phase 3 | Triple Negative Breast Cancer | - | - |
Topotecan | Phase 3 | Small Cell Lung Cancer | - | - |
HSK3486 | Phase 3 | Sedation or Anesthesia | - | - |
Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel | Phase 3 | HER2-low Breast Cancer | - | - |
Propofol | Phase 3 | Colonoscopy | - | - |
Irinotecan | Phase 3 | Esophageal Squamous Cell Carcinoma | - | - |
gemcitabine | Phase 3 | Nasopharyngeal Carcinoma | - | - |
KN035 plus Gemcitabine & oxaliplatin | Phase 3 | Biliary Tract Neoplasms | - | - |
Investigator's choice of chemotherapy | Phase 3 | Gastric Adenocarcinoma | - | - |
Pemetrexed+Cisplatin or Carboplatin | Phase 3 | Non-small Cell Lung Cancer | - | - |
Carboplatin | Phase 3 | Non-squamous Non-small Cell Lung Cancer | - | - |
BL-M05D1 | Phase 3 | Gastric Cancer | - | - |
Pertuzumab | Phase 3 | HER2-positive Breast Cancer | - | - |
SKB105 for injection Monotherapy | Phase 2 | Advanced Solid Tumors | - | - |
KN035 | Phase 2 | Solid Tumor | - | - |
BL-M02D1 | Phase 2 | Non-small Cell Lung Cancer | - | - |
KL590586 Capsule | Phase 2 | Advanced Solid Tumor | - | - |
PD-1 monoclonal antibody | Phase 2 | Extensive-stage Small-cell Lung Cancer | - | - |
Axitinib | Phase 2 | Renal Cancer | - | - |
Sacituzumab Tirumotecan | Phase 2 | Non-Small Cell Lung Cancer | - | - |
PD-1 | Phase 2 | Urothelial Carcinoma | - | - |
SI-B003 | Phase 2 | Esophageal Cancer | - | - |
PRT-064040 nasal spray | Phase 2 | Migraine | - | - |
SKB571 for injection | Phase 2 | Lung Cancer (Non-Small Cell) | - | - |
Clarithromycin | Phase 2 | Ovarian Epithelial Cancer | - | - |
Test product HY0001a for injection | Phase 2 | Solid Tumor | - | - |
Low Dose PRT042 nasal spray | Phase 2 | Major Depressive Disorder (MDD | - | - |
GNC-035 | Phase 2 | Non-hodgkin's Lymphoma | - | - |
Test product: HYP-2090PTSA | Phase 2 | Safety | - | - |
Envafolimab+Lenvatinib | Phase 2 | Advanced Endometrial Cancer | - | - |
AP or TP | Phase 2 | Non Small Cell Lung Cancer | - | - |
HY05350 for injection | Phase 2 | Advanced Solid Tumor | - | - |
SKB103 for injection monotherapy | Phase 2 | Advanced Solid Tumors | - | - |
SKB500 Powder for Injection | Phase 2 | Small Cell Lung Cancer | - | - |
Lenvatinib | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
Envafolimab | Phase 2 | Solid Tumor | - | - |
GNC-038 | Phase 2 | Diffuse Large B-cell Lymphoma | - | - |
BL-B01D1 for Injection | Phase 2 | Recurrent Glioblastoma | - | - |
Lenvatinib + Envafolimab | Phase 2 | Solid Tumors | - | - |
SKB518 | Phase 2 | Lung Carcinoma | - | - |
KL-A167 Injection | Phase 2 | Nasopharyngeal Carcinoma | - | - |
SKB518 for injection | Phase 2 | Advanced Gynecological Malignancies | - | - |
Osimertinib Mesylate Tablets | Phase 2 | Non-small Cell Lung Cancer | - | - |